Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

References

• Health NCIaNIo. SEER stat fact sheets: prostate cancer. 5/2015 ed. Surveillance Research Program, National Cancer Institute SEER*Stat (seer.cancer.gov/seerstat), 2015.
   Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the united states: estimates using a dynamic progression model. Plos One. 2015;10:e0139440.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–240.
   PubMedGoogle Scholar
• Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19:111–121.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–1418.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Stone NN, Yu EY, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664–669.
   PubMed Web of Science ®Google Scholar
• Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (6, 8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–674.
   PubMed Web of Science ®Google Scholar
• Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637–643.
   PubMed Web of Science ®Google Scholar
• Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–1190.
   PubMed Web of Science ®Google Scholar
• Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114–1120.
   PubMed Web of Science ®Google Scholar
• Umbehr MH, Muntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106–117.
   PubMed Web of Science ®Google Scholar
• Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–2925.
   PubMed Web of Science ®Google Scholar
• Smith MR, Cook R, Lee KA, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077–2085.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800–3806.
   PubMed Web of Science ®Google Scholar
• Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–2487.
   PubMed Web of Science ®Google Scholar
• Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–1033.
   PubMed Web of Science ®Google Scholar
• Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993;150:908–913.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a southwest oncology group trial (SWOG 9426). Cancer. 2008;112:2393–2400.
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Fernandes K, Bell D, et al. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol. 2011;185:848–854.
   PubMed Web of Science ®Google Scholar
• Zuckerman J, Given R. Degarelix induction followed by leuprolide maintenance: a new treatment paradigm?. Americal Urol Assoc Annu Meet. 2013. Poster 784.
   Google Scholar
• Miller K, Simson G, Goble S, et al. Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). Ther Adv Urol. 2015;7:105–115.
   PubMedGoogle Scholar
• Azad AA, Beardsley EK, Hotte SJ, et al. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naive castration-resistant prostate cancer. Invest New Drugs. 2014;32:746–752.
   PubMed Web of Science ®Google Scholar
• Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998;159:149–153.
   PubMed Web of Science ®Google Scholar
• Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a southwest oncology group study (SWOG 9235). Urology. 2001;58:53–58.
   PubMed Web of Science ®Google Scholar
• Lodde M, Lacombe L, Fradet Y. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 2010;76:1189–1193.
   PubMed Web of Science ®Google Scholar
• Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34:2098–2106.
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res. 2008;14:4526–4531.
   PubMed Web of Science ®Google Scholar
• Fowler JE Jr., Pandey P, Seaver LE, et al. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol. 1995;154:448–453.
   PubMed Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81:242–251.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149:607–609.
   PubMed Web of Science ®Google Scholar
• Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:1566–1572.
   PubMed Web of Science ®Google Scholar
• Yokomizo Y, Kawahara T, Miyoshi Y, et al. Efficacy of immediate switching from bicalutamide to flutamide as second-line combined androgen blockade. Biomed Res Int. 2016;2016:4083183.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440–448.
   PubMed Web of Science ®Google Scholar
• Pomerantz M, Manola J, Taplin ME, et al. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007;177:2146–2150.
   PubMed Web of Science ®Google Scholar
• Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer. 2002;1:81–89.
   PubMedGoogle Scholar
• Aggarwal R, Weinberg V, Small EJ, et al. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009;7:E71–E76.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Crawford ED, Shore ND, et al. Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: the results from IMAAGEN core study. J Clin Oncol. 2014;32(suppl; abstr 5086):5s.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Crawford ED, Shore ND, et al. IMAAGEN trial update: effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. J Clin Oncol. 2015;33(suppl; abstr 5053):5s.
   Google Scholar
• Hussain M, Corn P, Michaelson D, et al. Activity and safety of the investigational agent orteronel in men with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen: results of a phase 2 study. In: Proceedings of the 27th Annual European Association of Urology; 2012 Feb; Paris, France. p. 24–28.
   Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963–970.
   PubMed Web of Science ®Google Scholar
• Smith MR, Liu G, Shreeve SM, et al. A randomized double-blinded, comparative study of ARN-509 plus androgen deprivation therapy (ADT) veresus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): the SPARTAN trial. J Clin Oncol. 2014;32(suppl; abstr TPS5100):5s.
   PubMed Web of Science ®Google Scholar
• Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer–results of a randomized double-blind placebo-controlled trial: medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007;99:765–776.
   PubMedGoogle Scholar
• Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003;169:1143–1149.
   PubMed Web of Science ®Google Scholar
• Miller K, Moul JW, Gleave M, et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2013;16:187–192.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 2006;25:541–549.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–755.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.
   PubMed Web of Science ®Google Scholar
• Francini F, Pascucci A, Francini E, et al. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer. 2011;2011:258689.
   PubMedGoogle Scholar
• Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54:1089–1094.
   PubMed Web of Science ®Google Scholar
• Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005;4:55–60.
   PubMedGoogle Scholar
• Hellman S, Weichselbaum RR. Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol. 2005;2:60–61.
   PubMedGoogle Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
   PubMed Web of Science ®Google Scholar
• Klein E. Seeing and not believing: oligometastases and the future of metastatic prostate cancer. Eu Urology. 2015;67(5):864–865.
   PubMed Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12.
   PubMed Web of Science ®Google Scholar
• Conde Moreno AJ, Ferrer AC, Muelas SR, et al. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiat Oncol. 2014;9:258.
   PubMedGoogle Scholar